Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 12

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 12
---
 reference. Please refer to these subsequent reports for additional information relating to the risks associated with investing in our common shares.

Our business, financial condition or results of operations could be materially adversely affected by any of these risks. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. The trading price of our common shares could decline due to any of these risks, and you may lose all or part of your investment. This prospectus supplement, the accompanying prospectus and the incorporated documents also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned below. Forward-looking statements included in this prospectus supplement are based on information available to us on the date hereof, and all forward-looking statements in documents incorporated by reference are based on information available to us as of the date of each such document. We are under no obligation to update or alter such forward-looking statements whether as a result of new information, future events or otherwise, other than as required by applicable securities legislation.

#### Risks Relating to This Offering
**You will experience immediate dilution in
the book value per common share you purchase in this offering.**

Because the price per common share being offered hereby
is substantially higher than the book value per common share, you will suffer substantial dilution in the net tangible book value of the
common shares purchase in this offering. Based on the assumed public offering price of $2.53 per share, which was the last reported sale
price of our common shares on Nasdaq on September 5, 2025, and assuming that we sell all $4,006,544 of common shares under this prospectus
supplement, and after deducting commissions and estimated aggregate offering expenses payable by us, if you purchase common shares in
this offering, you will experience immediate and substantial dilution of $0.70 per share in the net tangible book value of the common
shares. See the section titled “Dilution” below for a more detailed discussion of the dilution you will incur if you
purchase common shares in this offering.

**Management will have broad discretion as to
the use of the net proceeds from this offering, and we may not use the proceeds effectively.**

We intend to use the net proceeds from
the sale of common shares by us in this offering for general corporate purposes, which may include working capital, capital expenditures
and research and development and manufacturing